Table 2.
Clinicopathologic Characteristics of Patients Undergoing Pancreatic Resection for Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma After Pre-Operative Chemotherapy
| All Patients (n=93) | Borderline Resectable (n=59) | Locally Advanced (n=34) | P | |
|---|---|---|---|---|
|
| ||||
| Operation (%) | 0.743 | |||
| Pancreaticoduodenectomy | 80 (86.0) | 50 (84.7) | 30 (88.2) | |
| Distal pancreatectomy | 11 (11.8) | 8 (13.6) | 3 (8.8) | |
| Other pancreatectomy | 2 (2.2) | 1 (1.7) | 1 (2.9) | |
|
| ||||
| Vascular Operation (%) | 0.030 | |||
| Venous resection | 12 (12.9) | 11 (18.6) | 1 (2.9) | |
| No venous resection | 81 (87.1) | 48 (81.4) | 33 (97.1) | |
|
| ||||
| Pathologic tumor size, cm (range) | 2.0 (0–6.6) | 2.5 (0–6.6) | 1.2 (0–3.7) | 0.001 |
|
| ||||
| T stage | 0.005 | |||
| T0 | 12 (12.9) | 7 (11.9) | 5 (14.7) | |
| T1 | 13 (14.0) | 4 (6.8) | 9 (26.5) | |
| T2 | 6 (6.5) | 5 (8.5) | 1 (2.9) | |
| T3 | 58 (62.4) | 43 (72.9) | 15 (44.1) | |
| T4 | 3 (3.2) | 0 | 3 (8.8) | |
| Not assessed | 1 (1.1) | 0 | 1 (2.9) | |
|
| ||||
| Grade | 0.214 | |||
| Well-differentiated | 16 (17.2) | 8 (13.6) | 8 (23.5) | |
| Moderately-differentiated | 46 (49.5) | 35 (59.3) | 11 (32.4) | |
| Poorly-differentiated | 15 (16.1) | 9 (15.3) | 6 (17.6) | |
| Unknown, no residual tumor | 12 (12.9) | 7 (11.9) | 5 (14.7) | |
| Unknown, not assessed | 4 (4.3) | 0 | 4(11.8) | |
|
| ||||
| N stage | 0.028 | |||
| N0 | 59 (63.4) | 33 (55.9) | 26 (76.5) | |
| N1 | 33 (35.5) | 26 (44.1) | 7 (20.6) | |
| Not assessed | 1 (1.1) | 0 | 1 (2.9) | |
|
| ||||
| Perineural invasion | 0.394 | |||
| Present | 64 (68.8) | 43 (72.9) | 21 (61.8) | |
| Absent | 26 (28.0) | 15 (25.4) | 11 (32.4) | |
| Unknown | 3 (3.3) | 1 (1.7) | 2(5.9) | |
|
| ||||
| Lymphovascular invasion | 0.428 | |||
| Present | 24 (25.8) | 17 (28.8) | 7 (20.6) | |
| Absent | 60 (64.5) | 37 (62.7) | 23 (67.6) | |
| Indeterminate | 6 (6.5) | 4 (6.8) | 2 (5.9) | |
| Unknown | 3 (3.3) | 1 (1.7) | 2 (5.9) | |
|
| ||||
| Margins (%) | 0.408 | |||
| Negative | 80 (86.0) | 51 (86.4) | 29 (85.3) | |
| Positive | 13 (14.0) | 8 (13.6) | 5 (14.7) | |
|
| ||||
| Histopathologic response (%) | 0.176 | |||
| Complete | 12 (12.9) | 7 (11.9) | 5 (14.7) | |
| Marked | 11 (11.8) | 5 (8.5) | 6 (17.6) | |
| Minimal to moderate | 14 (15.1) | 11 (18.6) | 3 (8.8) | |
| Poor to no response | 23(24.7) | 18 (30.5) | 5 (14.7) | |
| Unknown | 33 (33.5) | 18 (30.5) | 19 (55.9) | |
CT indicates computed tomography; cm, centimeters, CA 19-9, serum cancer antigen 19-9